# In Vivo Specificity of KUC 7483 CL Co-administered With Bisoprolol, Propranolol, and Acipimox in Healthy Male Subjects

> **NCT02256722** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 12 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** KUC 7483 CL
- **DRUG:** Bisoprolol
- **DRUG:** Propranolol
- **DRUG:** Acipimox
- **DRUG:** Salmeterol

## Key facts

- **NCT ID:** NCT02256722
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2005-11
- **Final completion:** —
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2014-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02256722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02256722, "In Vivo Specificity of KUC 7483 CL Co-administered With Bisoprolol, Propranolol, and Acipimox in Healthy Male Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02256722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*